Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program

Rosarin Sruamsiri, Nathorn Chaiyakunapruk, Samart Pakakasama, Somtawin Sirireung, Nintita Sripaiboonkij, Udomsak Bunworasate, Suradej Hongeng

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

Hematopoieticic stem cell transplantation is the only therapeutic option that can cure thalassemia disease. Reduced intensity hematopoietic stem cell transplantation (RI-HSCT) has demonstrated a high cure rate with minimal complications compared to other options. Because RI-HSCT is very costly, economic justification for its value is needed. This study aimed to estimate the cost-utility of RI-HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for adolescent and young adult with severe thalassemia in Thailand.
Original languageEnglish
Article number45
Pages (from-to)1 - 12
Number of pages12
JournalBMC Health Services Research
Volume13
Issue number1
DOIs
Publication statusPublished - 2013

Cite this